Trial · NCT07190534
The Effectiveness of Hydroxychloroquine Versus Methotrexate in the Treatment of Frontal Fibrosing Alopecia in Routine Clinical Care: a Patient Preference Trial (FFA Trial)
NCT07190534, Not yet recruiting, Erasmus Medical Center
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Effectiveness of Hydroxychloroquine Versus Methotrexate in the Treatment of Frontal Fibrosing Alopecia in Routine Clinical Care: a Patient Preference Trial (FFA Trial). Trials, record NCT07190534. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07190534
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Effectiveness of Hydroxychloroquine Versus Methotrexate in the Treatment of Frontal Fibrosing Alopecia in Routine Clinical Care: a Patient Preference Trial (FFA Trial)
- NCT number
- NCT07190534
- Status
- Not yet recruiting
- Enrollment
- 50 participants, estimated
- Lead sponsor
- Erasmus Medical Center
- Conditions
- Frontal Fibrosing Alopecia, Cicatricial Alopecia
- Interventions
- Hydroxychloroquine (HCQ), Methotrexate (MTX)
- First posted
- 2025-09-24
- Last updated
- 2025-09-29
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Frontal Fibrosing Alopecia Severity Score (FFASS) change | Baseline to 24 weeks | The FFASS is a validated scoring system (range 0-25) that captures extent of hairline recession, eyebrow loss, clinical signs of inflammation, and patient symptoms. The primary endpoint is the mean change in FFASS from baseline to 24 weeks, comparing the hydroxychloroquine and methotrexate cohorts. |
| Secondary | FFASS change over time | Baseline, Weeks 12, 24, 36, and 48 | Longitudinal change in disease severity as measured by FFASS across all follow-up visits. |
| Secondary | Health-Related Quality of Life (HRQoL) | Baseline, Weeks 12, 24, 36, and 48 | Change in patient-reported HRQoL measured by Skindex-29 (dermatology-specific). |
| Secondary | Health-Related Quality of Life (HRQoL) | Baseline, Weeks 12, 24, 36, and 48 | Change in patient-reported HRQoL measured by CASIS (hair disease-specific) questionnaire |
| Secondary | Adverse Events and Safety | Baseline through Week 48 | Number, type, and severity of adverse events associated with hydroxychloroquine or methotrexate, as reported during routine care monitoring. |
| Secondary | Cost-Effectiveness and Health Economic Outcomes | Baseline and Week 24 | Assessment of productivity losses, health care utilization, and broader well-being using EQ-5D-5L |
| Secondary | Cost-Effectiveness and Health Economic Outcomes | Baseline and Week 24 | Assessment of productivity losses, health care utilization, and broader well-being using iMCQ/iPCQ |
| Secondary | Cost-Effectiveness and Health Economic Outcomes | Baseline and Week 24 | Assessment of productivity losses, health care utilization, and broader well-being using ICECAP-A |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07190534
GET https://conductscience.org/api/trials/v1/NCT07190534/registered